James Prieto, MD
Colon & Rectal Surgery · San Antonio, TXNPI 1154580769
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (59.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 73.5% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2020 at $9,856 and has fallen 95.6% since, to $429 in 2025.
Across 149 payments — averaging $108.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$12K
- Johnson & Johnson$498
- Medtronic$495
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$479
- Davol Inc.$459
- Biom'up SA$300
- plus $2K from 21 others
What the payments were for
- Travel & lodging$1,3328%
- Food & beverage$5,28333%
- Education$9,59959%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 27 | $11,920 |
| Johnson & Johnson | 12 | $498 |
| Medtronic | 6 | $495 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $479 |
| Davol Inc. | 10 | $459 |
| Biom'up SA | 2 | $300 |
| Covidien LP | 3 | $277 |
| Braintree Laboratories, Inc. | 17 | $260 |
| Baxter Healthcare | 5 | $195 |
| Smith+Nephew | 5 | $181 |
| Biom'up France SAS | 1 | $149 |
| Redhill Biopharma Inc. | 4 | $146 |
| Myriad Genetic Laboratories, Inc. | 3 | $144 |
| Pacira Pharmaceuticals Incorporated | 2 | $136 |
| GI Supply, Inc. | 1 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $110 |
| Aroa Biosurgery Incorporated | 2 | $51 |
| Aimmune Therapeutics, Inc. | 2 | $50 |
| Acell, Inc. | 1 | $37 |
| Olympus America Inc. | 1 | $34 |
| Stryker | 1 | $31 |
| Integra Lifesciences Corporation | 1 | $26 |
| TELA Bio, Inc. | 1 | $25 |
| Heron Therapeutics, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $20 |
| Ambu Inc. | 1 | $18 |
| Kerecis Limited | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$11,051
- HEMOBLAST$300
- Phasix Mesh$262
- INTERSTIM$253
- HemoBlast Bellows$149
- Harmonic$120
- Enseal$120
- EXPAREL$117
- iDrive$110
- EVICEL Fibrin Sealant (Human)$108
- Enseal X1 5mm$108
- LUCEMYRA$100
How this compares
$16,214 in reported general payments places this provider in the 80th percentile of 200 colon & rectal surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 21 | $20,037 |
| TrulancePlecanatide | 15 | $13,942 |
| Colestipol Hcl | 42 | $5,957 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 22 | $3,737 |
| Dicyclomine Hcl | 43 | $2,227 |
| Lubiprostone | 28 | $2,091 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 13 | $1,648 |
| Cholestyramine LightCholestyramine | 16 | $1,233 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 13 | $834 |
| Hydrocortisone | 59 | $705 |
| Lidocaine | 22 | $546 |
| ConstuloseLactulose | 15 | $388 |
| Silver Sulfadiazine | 39 | $356 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 47 | $241 |
| Lactulose | 11 | $221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $479 | $13,94215 claims |
| Braintree Laboratories, Inc.Suflave | $260 | $1,64813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 200 colon & rectal surgery providers in Texas.
Other colon & rectal surgery in San Antonio
- Christopher de JesusSan Antonio$201K
- William LewisSan Antonio$85K
- Jaime MayoralSan Antonio$84K
- Michael KellerSan Antonio$50K
- Maria Martinez UgarteSan Antonio$47K
- Rolando SaenzSan Antonio$15K
- Mario AlcantaraSan Antonio$14K
- Thiru LakshmanAustin$756K
- Diego Marines CopadoHouston$462K
- Bidhan DasSugar Land$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.